Corcept Therapeutics's three largest insider shareholders as of September 29, 2026 are Joseph K Belanoff (Chief Executive Officer, 2.87Mn shares), Joseph K Belanoff (Chief Executive Officer, 2.48Mn shares), G Leonard Jr Baker (Director, 1.15Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Joseph K Belanoff | Chief Executive Officer | 0 | 2,865,489 | 2,865,489 | 43.5% | 02 Jun, 2026 |
| 2 | G Leonard Jr Baker | Director | 1,146,631 | 0 | 1,146,631 | 17.4% | 19 Mar, 2026 |
| 3 | David L Mahoney | Director | 0 | 1,133,539 | 1,133,539 | 17.2% | 20 Aug, 2026 |
| 4 | James N Wilson | Director | 0 | 1,064,543 | 1,064,543 | 16.2% | 16 Sep, 2026 |
| 5 | Hazel Hunt | Chief Scientific Officer | 255,437 | 0 | 255,437 | 3.9% | 11 Feb, 2026 |
| 6 | Gary Charles Robb | Chief Business Officer | 14,056 | 60,287 | 74,343 | 1.1% | 28 Sep, 2026 |
| 7 | Atabak Mokari | Chief Financial Officer | 16,304 | 0 | 16,304 | 0.2% | 03 Sep, 2026 |
| 8 | Sean Maduck | Chief Commercial Officer | 9,938 | 0 | 9,938 | 0.2% | 03 Sep, 2026 |
| 9 | Joseph Douglas Lyon | Chief Accounting Officer | 5,683 | 0 | 5,683 | 0.1% | 16 Sep, 2026 |
| 10 | William Guyer | Chief Development Officer | 4,313 | 0 | 4,313 | 0.1% | 03 Sep, 2026 |
| 11 | Roberto Wandenkolk Vieira | President, Oncology | 3,946 | 0 | 3,946 | 0.1% | 18 Sep, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 24 Sep, 2026 | Gary Charles Robb | Chief Business Officer | Disposed G | 17,100 | $0.00 | $0 | 14,056 | Direct |
| 24 Sep, 2026 | Gary Charles Robb | Chief Business Officer | Acquired G | 5,000 | $0.00 | $0 | 20,571 | Indirect |
| 24 Sep, 2026 | Gary Charles Robb | Chief Business Officer | Acquired G | 5,000 | $0.00 | $0 | 20,571 | Indirect |
| 17 Sep, 2026 | Gary Charles Robb | Chief Business Officer | Acquired M | 17,493 | $8.27 | $144.67K | 31,156 | Direct |
| 16 Sep, 2026 | Roberto Wandenkolk Vieira | President, Oncology | Disposed S | 296 | $100.82 | $29.84K | 3,946 | Direct |
| 17 Sep, 2026 | Gary Charles Robb | Chief Business Officer | Disposed M | 17,493 | $0.00 | $0 | 182,507 | Direct |
| 01 Sep, 2026 | William Guyer | Chief Development Officer | Acquired A | 164 | $113.38 | $18.59K | 4,149 | Direct |
| 01 Sep, 2026 | Joseph Douglas Lyon | Officer | Acquired A | 130 | $113.38 | $14.74K | 5,625 | Direct |
| 01 Sep, 2026 | Gary Charles Robb | Chief Business Officer | Acquired A | 164 | $113.38 | $18.59K | 13,590 | Direct |
| 01 Sep, 2026 | Atabak Mokari | Chief Financial Officer | Acquired A | 138 | $113.38 | $15.65K | 16,268 | Direct |
| 01 Sep, 2026 | Sean Maduck | Officer | Acquired M | 25,000 | $8.27 | $206.75K | 34,755 | Direct |
| 01 Sep, 2026 | Roberto Wandenkolk Vieira | President, Oncology | Acquired A | 138 | $113.38 | $15.65K | 4,206 | Direct |
| 01 Sep, 2026 | William Guyer | Chief Development Officer | Acquired A | 164 | $0.00 | $0 | 4,313 | Direct |
| 01 Sep, 2026 | Joseph Douglas Lyon | Officer | Acquired A | 130 | $0.00 | $0 | 5,755 | Direct |
| 01 Sep, 2026 | Atabak Mokari | Chief Financial Officer | Acquired A | 138 | $0.00 | $0 | 16,406 | Direct |
| 01 Sep, 2026 | Gary Charles Robb | Chief Business Officer | Acquired A | 164 | $0.00 | $0 | 13,754 | Direct |
| 01 Sep, 2026 | Sean Maduck | Officer | Disposed S | 11,730 | $113.94 | $1.34Mn | 23,025 | Direct |
| 01 Sep, 2026 | Roberto Wandenkolk Vieira | President, Oncology | Acquired A | 138 | $0.00 | $0 | 4,344 | Direct |
| 01 Sep, 2026 | Sean Maduck | Officer | Disposed S | 10,989 | $114.71 | $1.26Mn | 12,036 | Direct |
| 02 Sep, 2026 | Roberto Wandenkolk Vieira | President, Oncology | Disposed F | 102 | $113.38 | $11.56K | 4,242 | Direct |